Compare Gigacloud Technology Inc (GCT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Gigacloud Technology Inc trades at $38.21 (market cap $1.40B), while Regeneron Pharmaceuticals Inc trades at $677.59 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 49.8× Gigacloud Technology Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| GCT | REGN | |
|---|---|---|
Market Cap | $1.40B | $69.66B |
Sector | Technology | Health |
52-Week High | $51.80 | $812.27 |
52-Week Low | $20.97 | $542.52 |
Enterprise Value | $1.51B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.
GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
